Do analysts prefer DBVT or GMTX?

DBV Technologies presently has a consensus price target of $48.50, indicating a potential upside of 233.33%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor DBVT or GMTX?

In the previous week, DBV Technologies and DBV Technologies both had 1 articles in the media. Gemini Therapeutics' average media sentiment score of 0.75 beat DBV Technologies' score of 0.59 indicating that Gemini Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gemini Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABCL or DBVT?

In the previous week, AbCellera Biologics had 4 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for AbCellera Biologics and 1 mentions for DBV Technologies. AbCellera Biologics' average media sentiment score of 1.03 beat DBV Technologies' score of 0.59 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DBVT or IDYA?

In the previous week, IDEAYA Biosciences had 4 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for IDEAYA Biosciences and 1 mentions for DBV Technologies. IDEAYA Biosciences' average media sentiment score of 0.66 beat DBV Technologies' score of 0.59 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, DBVT or VCYT?

Veracyte has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DBV Technologies $5.64M 162.22 -$146.95M -$3.51 N/A Veracyte $517.15M 6.58 $66.35M $1.41 30.01

Is DBVT or VCYT more profitable?

Veracyte has a net margin of 20.37% compared to DBV Technologies' net margin of -3,506.53%. Veracyte's return on equity of 9.26% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% Veracyte 20.37% 9.26% 8.61%

Does the media favor DBVT or VCYT?

In the previous week, Veracyte had 9 more articles in the media than DBV Technologies. MarketBeat recorded 10 mentions for Veracyte and 1 mentions for DBV Technologies. Veracyte's average media sentiment score of 1.29 beat DBV Technologies' score of 0.59 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DBVT or CLDX?

In the previous week, Celldex Therapeutics had 2 more articles in the media than DBV Technologies. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for DBV Technologies. Celldex Therapeutics' average media sentiment score of 0.90 beat DBV Technologies' score of 0.59 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DBV Technologies (DBVT) Competitors

$14.55 +0.31 (+2.18%)

As of 08/21/2026 04:00 PM Eastern

Compare

DBVT vs. GMTX, ABCL, IDYA, VCYT, and CLDX

Should you buy DBV Technologies stock or one of its competitors? DBV Technologies's main competitors and comparable companies include Gemini Therapeutics (GMTX), AbCellera Biologics (ABCL), IDEAYA Biosciences (IDYA), Veracyte (VCYT), and Celldex Therapeutics (CLDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DBV Technologies compare to Gemini Therapeutics?

DBV Technologies (NASDAQ:DBVT) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, DBV Technologies and DBV Technologies both had 1 articles in the media. Gemini Therapeutics' average media sentiment score of 0.75 beat DBV Technologies' score of 0.59 indicating that Gemini Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gemini Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Gemini Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Gemini Therapeutics' return on equity of -38.78% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Gemini Therapeutics	N/A	-38.78%	-35.88%

DBV Technologies has a beta of -0.93, suggesting that its share price is 193% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

DBV Technologies presently has a consensus price target of $48.50, indicating a potential upside of 233.33%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics has lower revenue, but higher earnings than DBV Technologies. Gemini Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	162.22	-$146.95M	-$3.51	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Summary

Gemini Therapeutics beats DBV Technologies on 9 of the 15 factors compared between the two stocks.

How does DBV Technologies compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

AbCellera Biologics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.93, indicating that its share price is 193% less volatile than the broader market.

In the previous week, AbCellera Biologics had 4 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for AbCellera Biologics and 1 mentions for DBV Technologies. AbCellera Biologics' average media sentiment score of 1.03 beat DBV Technologies' score of 0.59 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics presently has a consensus target price of $12.83, suggesting a potential upside of 13.37%. DBV Technologies has a consensus target price of $48.50, suggesting a potential upside of 233.33%. Given DBV Technologies' higher probable upside, analysts clearly believe DBV Technologies is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

AbCellera Biologics has a net margin of -248.83% compared to DBV Technologies' net margin of -3,506.53%. AbCellera Biologics' return on equity of -17.49% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AbCellera Biologics has higher revenue and earnings than DBV Technologies. AbCellera Biologics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	46.20	-$146.41M	-$0.54	N/A
DBV Technologies	$5.64M	162.22	-$146.95M	-$3.51	N/A

Summary

AbCellera Biologics beats DBV Technologies on 10 of the 14 factors compared between the two stocks.

How does DBV Technologies compare to IDEAYA Biosciences?

DBV Technologies (NASDAQ:DBVT) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

IDEAYA Biosciences has a net margin of -75.93% compared to DBV Technologies' net margin of -3,506.53%. IDEAYA Biosciences' return on equity of -16.73% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

IDEAYA Biosciences has higher revenue and earnings than DBV Technologies. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	162.22	-$146.95M	-$3.51	N/A
IDEAYA Biosciences	$218.71M	15.94	-$113.70M	-$1.94	N/A

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

DBV Technologies presently has a consensus price target of $48.50, suggesting a potential upside of 233.33%. IDEAYA Biosciences has a consensus price target of $50.13, suggesting a potential upside of 26.35%. Given DBV Technologies' higher possible upside, equities research analysts clearly believe DBV Technologies is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

In the previous week, IDEAYA Biosciences had 4 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for IDEAYA Biosciences and 1 mentions for DBV Technologies. IDEAYA Biosciences' average media sentiment score of 0.66 beat DBV Technologies' score of 0.59 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

DBV Technologies has a beta of -0.93, meaning that its share price is 193% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

Summary

IDEAYA Biosciences beats DBV Technologies on 13 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Veracyte?

DBV Technologies (NASDAQ:DBVT) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

DBV Technologies has a beta of -0.93, indicating that its share price is 193% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

In the previous week, Veracyte had 9 more articles in the media than DBV Technologies. MarketBeat recorded 10 mentions for Veracyte and 1 mentions for DBV Technologies. Veracyte's average media sentiment score of 1.29 beat DBV Technologies' score of 0.59 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	162.22	-$146.95M	-$3.51	N/A
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01

DBV Technologies currently has a consensus price target of $48.50, suggesting a potential upside of 233.33%. Veracyte has a consensus price target of $54.33, suggesting a potential upside of 28.42%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

71.7% of DBV Technologies shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 1.6% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Veracyte has a net margin of 20.37% compared to DBV Technologies' net margin of -3,506.53%. Veracyte's return on equity of 9.26% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Veracyte	20.37%	9.26%	8.61%

Summary

Veracyte beats DBV Technologies on 14 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Celldex Therapeutics?

DBV Technologies (NASDAQ:DBVT) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

DBV Technologies currently has a consensus target price of $48.50, suggesting a potential upside of 233.33%. Celldex Therapeutics has a consensus target price of $56.08, suggesting a potential upside of 38.89%. Given DBV Technologies' higher probable upside, equities analysts plainly believe DBV Technologies is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

DBV Technologies has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	162.22	-$146.95M	-$3.51	N/A
Celldex Therapeutics	$1.54M	2,059.12	-$258.76M	-$4.35	N/A

DBV Technologies has a beta of -0.93, meaning that its share price is 193% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Celldex Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Celldex Therapeutics' return on equity of -52.35% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Celldex Therapeutics	N/A	-52.35%	-47.61%

71.7% of DBV Technologies shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Celldex Therapeutics had 2 more articles in the media than DBV Technologies. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for DBV Technologies. Celldex Therapeutics' average media sentiment score of 0.90 beat DBV Technologies' score of 0.59 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats DBV Technologies on 10 of the 16 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DBVT vs. The Competition

Export

Metric	DBV Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$914.83M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-4.15	11.62	272.60	24.24
Price / Sales	162.22	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	5.71	16.80	13.05	6.20
Net Income	-$146.95M	-$12.50M	$3.47B	$348.59M
7 Day Performance	3.78%	3.29%	2.09%	0.08%
1 Month Performance	4.98%	8.23%	6.64%	3.88%
1 Year Performance	45.50%	55.05%	25.02%	16.98%

DBV Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DBVT DBV Technologies	2.6435 of 5 stars	$14.55 +2.2%	$48.50 +233.3%	+45.5%	$914.83M	$5.64M	N/A	80
GMTX Gemini Therapeutics	N/A	$80.05 +1.5%	N/A	+33.6%	$3.47B	N/A	N/A	30	News Coverage High Trading Volume
ABCL AbCellera Biologics	2.307 of 5 stars	$11.21 +0.0%	$12.83 +14.5%	+157.9%	$3.42B	$66.17M	N/A	500	Positive News
IDYA IDEAYA Biosciences	2.6882 of 5 stars	$37.55 +2.8%	$50.13 +33.5%	+57.9%	$3.30B	$234.13M	N/A	80
VCYT Veracyte	4.3835 of 5 stars	$40.93 -2.7%	$54.33 +32.7%	+36.5%	$3.29B	$561.90M	29.01	790	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DBVT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DBV Technologies (DBVT) Competitors

DBVT vs. GMTX, ABCL, IDYA, VCYT, and CLDX

How does DBV Technologies compare to Gemini Therapeutics?

Summary

How does DBV Technologies compare to AbCellera Biologics?

Summary

How does DBV Technologies compare to IDEAYA Biosciences?

Summary

How does DBV Technologies compare to Veracyte?

Summary

How does DBV Technologies compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DBV Technologies (DBVT) Competitors

DBVT vs. GMTX, ABCL, IDYA, VCYT, and CLDX

How does DBV Technologies compare to Gemini Therapeutics?

Does the media favor DBVT or GMTX?

Do insiders & institutionals have more ownership in DBVT or GMTX?

Is DBVT or GMTX more profitable?

Which has more risk & volatility, DBVT or GMTX?

Do analysts prefer DBVT or GMTX?

Which has higher earnings and valuation, DBVT or GMTX?

Summary

How does DBV Technologies compare to AbCellera Biologics?

Which has more volatility & risk, ABCL or DBVT?

Does the media refer more to ABCL or DBVT?

Do analysts recommend ABCL or DBVT?

Is ABCL or DBVT more profitable?

Do insiders & institutionals believe in ABCL or DBVT?

Which has better valuation & earnings, ABCL or DBVT?

Summary

How does DBV Technologies compare to IDEAYA Biosciences?

Is DBVT or IDYA more profitable?

Which has better valuation & earnings, DBVT or IDYA?

Do insiders and institutionals hold more shares of DBVT or IDYA?

Do analysts recommend DBVT or IDYA?

Does the media favor DBVT or IDYA?

Which has more volatility and risk, DBVT or IDYA?

Summary

How does DBV Technologies compare to Veracyte?

Which has more volatility & risk, DBVT or VCYT?

Does the media favor DBVT or VCYT?

Which has preferable valuation and earnings, DBVT or VCYT?

Do analysts rate DBVT or VCYT?

Do insiders and institutionals hold more shares of DBVT or VCYT?

Is DBVT or VCYT more profitable?

Summary

How does DBV Technologies compare to Celldex Therapeutics?

Do analysts recommend DBVT or CLDX?

Which has preferable valuation & earnings, DBVT or CLDX?

Which has more risk & volatility, DBVT or CLDX?

Is DBVT or CLDX more profitable?

Do insiders and institutionals believe in DBVT or CLDX?

Does the media prefer DBVT or CLDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools